SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-303689
Filing Date
2020-11-25
Accepted
2020-11-25 16:40:57
Documents
14
Period of Report
2020-11-24
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d30774d8k.htm   iXBRL 8-K 25477
2 EX-99.1 d30774dex991.htm EX-99.1 11412
6 GRAPHIC g30774img01.jpg GRAPHIC 11301
  Complete submission text file 0001193125-20-303689.txt   182544

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fstx-20201124.xsd EX-101.SCH 2734
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fstx-20201124_lab.xml EX-101.LAB 18693
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fstx-20201124_pre.xml EX-101.PRE 11779
7 EXTRACTED XBRL INSTANCE DOCUMENT d30774d8k_htm.xml XML 3593
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37718 | Film No.: 201351217
SIC: 2834 Pharmaceutical Preparations